FDA Clears PearlBone Bone Graft Made From Pearl Shell

A bone graft made from pearl shell can now be sold in the United States. Marine Biomedical, a Western Australian company based in Broome, has received Food and Drug Administration 510(k) clearance for PearlBone Putty 1600, a bone graft substitute developed from nacre, the iridescent mother-of-pearl material inside pearl shell. The clearance, announced November 3, 2026, makes PearlBone the first nacre-derived bone graft substitute cleared for fracture repair. It can be marketed in the U.S. for its cleared indications.

The raw material comes from Pinctada maxima, the large pearl oyster farmed along Western Australia's Kimberley coast. Marine Biomedical was established in 2021 through a partnership between Willie Creek Pearls, a local pearl producer, and research expertise from the University of Western Australia. A purpose-built manufacturing facility followed in Broome in 2022. A patented process, first filed in 2018, converts the shell's nacre into a bone mineral matrix composite that surgeons can use to fill and support broken bone while the body rebuilds its own.

The commercial prize is the size of the American market. The broader U.S. bone grafts and substitutes market is estimated at $1.1 billion in 2026, with forecast growth of 6.2 percent a year through 2033, and it's the largest orthopedics market in the world. Chief executive Rolee Kumar called the clearance the company's ticket to the United States. Bone graft substitutes compete against harvested human bone, synthetic ceramics and the patient's own bone, each with supply, cost or second-surgery trade-offs a shell-derived product aims to sidestep.

Clearance isn't the same as products on shelves. The company itself says FDA clearance is a first step and that further regulatory and commercial hurdles remain before PearlBone can actually be sold in the United States. It hasn't disclosed a launch date or sales forecast. The same caution applies in reverse: the company hopes to bring PearlBone to Australian customers in the future, meaning the product cleared first in a foreign market while its home market waits, and it flags dental work as a possible later application.

There's an Australian shareholder angle riding on the decision. Regenerative medicine company Orthocell holds a 12 percent equity interest in Marine Biomedical after a strategic investment totaling A$1.05 million, completed in January 2026. Orthocell also holds a first right of refusal over global distribution of PearlBone and future bone repair products, but it doesn't hold U.S. distribution rights today. Any role in the American launch depends on exercising that right and agreeing terms that haven't been announced.

What the clearance proves is narrower and still significant: a material the pearl industry grows for jewelry and buttons passed the FDA's substantial-equivalence bar as a medical device for repairing fractures. The years of preclinical evaluation, manufacturing validation and regulatory preparation the company describes are the unglamorous part, and they're done. The remaining fight is commercial, fought in hospital purchasing departments rather than laboratories, and it starts from a shell most people only ever see as shine.